Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2003
09/09/2003US6617313 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)benzofuran-7-C-beta -D-glucopyranoside, obtained by solvent extraction of powdered hardwood of Pterocarpus marsupium; treatment of diabetes
09/09/2003US6617134 Dimer of molecular variant of apolipoprotein and processes for the production thereof
09/09/2003US6617122 Contacting a compound with a polypeptide, in the presence of adenosine triphosphate (ATP) and detecting its binding or hydrolysis of ATP; use in treatment of coronary artery disease
09/09/2003US6616940 Feeding said animal an effective amount of Vitamin A for a time sufficient to reduce adiposity; pet foods
09/09/2003US6616926 Methods of modulating lipid metabolism and storage
09/09/2003CA2263566C Substituted 6,5-hetero-bicyclic derivatives
09/09/2003CA2239498C Bioartificial devices and cellular matrices therefor
09/09/2003CA2087298C Bile acid sulfurated derivatives
09/09/2003CA2036770C Inhibitors of nitric oxide biosynthesis
09/04/2003WO2003073107A2 Neuropeptide receptor and uses thereof
09/04/2003WO2003072787A2 Method for detection of leptin receptor ligands
09/04/2003WO2003072780A1 Novel proteins, dnas thereof and use of the same
09/04/2003WO2003072715A2 Gasp1: a follistatin domain containing protein
09/04/2003WO2003072714A2 Follistatin domain containing proteins
09/04/2003WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/04/2003WO2003072580A1 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES
09/04/2003WO2003072579A1 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
09/04/2003WO2003072577A1 Thiazole derivatives as npy receptor antagonists
09/04/2003WO2003072573A1 Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
09/04/2003WO2003072572A1 Beta3-adrenergic receptor agonists
09/04/2003WO2003072571A1 Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist
09/04/2003WO2003072570A1 Antidiabetic agents
09/04/2003WO2003072569A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
09/04/2003WO2003072558A2 Arylsulfone derivatives
09/04/2003WO2003072557A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
09/04/2003WO2003072556A1 Glutaminyl based dpiv inhibitors
09/04/2003WO2003072555A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
09/04/2003WO2003072554A1 Azole compounds
09/04/2003WO2003072547A1 PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
09/04/2003WO2003072537A2 Selective protein tyrosine phosphatatase inhibitors
09/04/2003WO2003072532A1 Ester compound and medicinal use thereof
09/04/2003WO2003072198A1 The use of a benzenesulfonamide compound in the treatment of obesity
09/04/2003WO2003072197A1 Acc inhibitors
09/04/2003WO2003072195A2 Method for administering glp-1 molecules
09/04/2003WO2003072159A1 N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/04/2003WO2003072135A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
09/04/2003WO2003072121A1 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
09/04/2003WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
09/04/2003WO2003072109A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases
09/04/2003WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones
09/04/2003WO2003072102A1 Peroxisome proliferator activated receptor modulators
09/04/2003WO2003072100A1 Peroxisome proliferator activated receptor modulators
09/04/2003WO2003072099A1 Peroxisome proliferator activated receptor modulators
09/04/2003WO2003072098A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
09/04/2003WO2003072088A1 Capsule for the time-delayed dispensing of nutrients and/or active substances
09/04/2003WO2003072056A2 Intranasal administration of mc4-r agonists
09/04/2003WO2003072035A2 Compositions and methods for the treatment of immune related diseases
09/04/2003WO2003072027A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof
09/04/2003WO2003071884A1 Compound containing creatine, an acid component and/or a complexing agent
09/04/2003WO2003064451A3 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
09/04/2003WO2003062209A3 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
09/04/2003WO2003051805A3 Substituted phenyl naphthalenes as estrogenic agents
09/04/2003WO2003045313A3 2-aminoquinoline compounds
09/04/2003WO2003037891A8 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
09/04/2003WO2003033681A3 Composition comprising a lactobacillus pentosus strain and uses thereof
09/04/2003WO2003030922A3 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2003029423A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/04/2003WO2003028739A3 Composition for preventing or treating hyperlipidemia or hyperglycemia comprising a polymer or its salt
09/04/2003WO2003028730A3 Pharmaceutical combinations of pde-v inhibitors and other agents
09/04/2003WO2003020265A3 Compositions comprising pectin and ascorbic acid
09/04/2003WO2003002593A3 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
09/04/2003WO2002101069A3 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
09/04/2003WO2002079238A3 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2002068387A8 Acylated piperidine derivatives as melanocortin-4 receptor agonists
09/04/2003WO2002064792A3 Molecules for disease detection and treatment
09/04/2003WO2002055698A3 Transcriptional mediators of blood vessel development and endothelial differentiation
09/04/2003WO2002053775A3 Identification of genetic determinants of polymorphic cyp3a5 expression
09/04/2003WO2002046426A3 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
09/04/2003WO2002020769A9 Human and mouse targeting peptides identified by phage display
09/04/2003WO2002015892A3 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
09/04/2003WO2002003977A3 Combinations of statins, estrogenic agents and optionally estrogens
09/04/2003WO2001085193A3 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
09/04/2003WO2001057261A9 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
09/04/2003US20030167525 Desaturase genes and uses thereof
09/04/2003US20030166945 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
09/04/2003US20030166928 Central nervous system disorders, sleep disorders, eating disorders. sexual disorders, hypotensive agents
09/04/2003US20030166927 1,5-Benzothiazepines and their use as hypolipidaemics
09/04/2003US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents
09/04/2003US20030166847 Novel human leptin receptor gene-related protein
09/04/2003US20030166730 Amide derivatives for the treatment of diseases mediated by cytokines
09/04/2003US20030166725 Compounds active at the glucocorticoid receptor
09/04/2003US20030166720 Administering a therapeutic combination comprising a first amount of a fibric acid derivative and a second amount of a cholesteryl ester transfer protein inhibitor effective for treatment of hyperlipidemic conditions
09/04/2003US20030166701 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
09/04/2003US20030166697 Divalent aromatic heterocyclic compounds useful in prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like
09/04/2003US20030166690 Use of compounds for decreasing activity of hormone-sensitive
09/04/2003US20030166689 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
09/04/2003US20030166686 Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
09/04/2003US20030166671 Amorphous polymorphic forms by grinding or pulverizing; having a distinctive X-ray powder diffraction pattern; anti-tumor and -carcinogenic agents; administered by mouth, intravenous injection and inhalation
09/04/2003US20030166668 Substituted heteroarylalkanoic acids
09/04/2003US20030166663 E.g.,4-tert-butyl-N-(4-piperazin-1-yl-quinolin-6-yl)benzene-su lfonamide or 5-chloro-3-methyl-benzo(b)thiophene-2-sulfonic acid (4-piperazin-1-yl-quinolin-6-yl) amide; obesity; food intake reduction; bind to 5-HT6 receptors; antiseraton agents
09/04/2003US20030166653 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
09/04/2003US20030166646 Nitric oxide synthase inhibitors such as 4-(morpholin-4-yl methyl)-4,5-dihydro-1,3-thiazol-2-ylamine, administered for prophylaxis of neurodegenerative diseases
09/04/2003US20030166644 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
09/04/2003US20030166637 Amines such as 9-(4-(4-(benzothiazol-2-yl)-piperazin-1-yl)-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoroethyl) amide, used as microsomal triglyceride transfer protein antagonists, to prevent atherosclerosis or hyperlipemia
09/04/2003US20030166634 Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists
09/04/2003US20030166633 Pyridinylimidazoles
09/04/2003US20030166630 Amino acid derivatives and their use as medicines
09/04/2003US20030166628 Drugs such as 3-(4-chlorobenzo(b)thiophen-2-yl)-5,6-dihydro-imidazo(2,1-b)thiazole, used as hydroxytryptamine and/or noradrenaline reuptake inhibitors; anxiolytic agents
09/04/2003US20030166614 Daily administering a mixture of anticholesterol agents comprising fish oil concentrate, niacin, and lecithin
09/04/2003US20030166613 A macrocyclic diterpene plant extract for treating viral infections; A computer program product for storing the library information of candidate compounds
1 ... 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 ... 1298